Pedro de Noronha Pissarra, Ph.D.
Pedro obtained both his B.Sc. and Ph.D. in Biotechnology from Kings College London (University of London). He carried out research at several institutions, including the Chemical Engineering Department of Massachusetts Institute of Technology (M.I.T.), Cambridge, USA and at the Centre for Process Biotechnology (CPB) of the Technical University of Denmark, Lyngby, Denmark. Following his Doctoral degree he specialized in medical sciences and oncology. After his Postdoctoral training he undertook a 12 month Masters Programme in Management at the IC2 Institute of the University of Texas, Austin, USA.
Pedro was a visiting professor at the Catholic University of Porto during 2000-2007 where he delivered lectures in biopharmaceutical sciences. He was the Chairman & Chief Executive Officer of Biotecnol SA, in Lisbon Portugal, up to March 2012. He currently holds the position of Executive Chairman and is an integral part of its Board of Directors. Prior to his current position he was a Board Member of Vida Rhein Corporation SA – a German-Portuguese joint venture, part of the Rhein Biotech NV group, dedicated to the development of Hepatitis B vaccines and other biosimilar products.
Pedro was the founder of the Portuguese Bio-industries Association (APBio) and later had it incorporated into EuropaBio (the European Bioindustries Association). Between 1998 and 2005 he was the Chairman of APBio, and has been widely recognized as one of the key individuals in establishing and promoting the biotechnology industry in Portugal. Between 1997 and 2000 he was a member of the Advisory Group of the Biotechnology & Finance Forum, organized by the European Association of Security Dealers and Automated Quotations (EASDAQ), and the European Commission’s DG Research. He was a member of the National Council of the National Entrepreneurs Association (ANJE). Pedro was extensively involved in several EuropaBio initiatives and task forces. For several years he was a member of the Policy & Operations Council and Coordination Council, the Emerging Enterprises Sub-Board and the Biosimilar Products Task-Force.
He has been involved since 1997 in several expert panels advising the European Commission in its biotechnology policies. He has also been involved in several Advisory Committees for the Portuguese Government. Pedro was a member of the Superior Counsel for Science, Technology and Innovation for the Portuguese Government, where he advised the Minister of Science and Technology in the implementation of the National Innovation Plan during the mandate of Dr. José Manuel Durão Barroso as Prime Minister of Portugal. Other recognitions included his participation in the Honor committee of the President of the Republic of Portugal, Prof. Aníbal Cavaco Silva in 2006.
Pedro has been awarded the Medal of Merit by the Oeiras Council in Portugal in recognition for his role in promoting entrepreneurship and for services provided to the council of Oeiras, where Biotecnol SA, the biotech pioneer in Portugal started its operations and is present since 1997.
Neill Moray Mackenzie, Ph.D.
Neill is an internationally networked pharmaceutical executive with an extensive operational, business, commercial, licensing and R&D background in a range of therapeutic areas. He holds a PhD in immunology and post-doctoral work at the National Institute for Medical Research with the MRC. He joined Wellcome plc as Head of the Immunology Department continuing with Mallinckrodt Inc.
Over the last eighteen years, he has served on the Boards of listed (both the full London Stock Exchange (LSE) and the Alternative Investment Market (AIM)) and private companies in the UK and Germany as an Executive Director with P&L responsibilities, and has raised over $150 million equity capital from private and public funds.
Nigel Blackburn, Ph.D
Nigel leads the Centre for Drug Development (CDD) at CRUK and is responsible for CRUK's early drug development programmes, which include pre-clinical development and early clinical testing of novel anti-cancer agents. Nigel and his team at the CDD are currently managing the early development of over 20 novel agents. Nigel joined CRUK in May 2009 as Director of Drug Development, having previously held a variety of senior leadership roles in the pharma and biotech industries. He has experience of all phases of clinical drug development and a broad range of therapeutic modalities and disease areas. Nigel holds a biochemistry degree and PhD in physiology.